Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

BUY
$7.9 - $21.32 $326,270 - $880,516
41,300 Added 317.69%
54,300 $1.16 Million
Q4 2023

Feb 14, 2024

BUY
$2.48 - $9.65 $32,240 - $125,450
13,000 New
13,000 $124,000

Others Institutions Holding FUSN

About Fusion Pharmaceuticals Inc.


  • Ticker FUSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,390,500
  • Description
  • Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order ...
More about FUSN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.